The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...
There was no significant difference in 10-year overall survival between women who received radiation after surgery and those ...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with “Good-Risk” DCIS Who Forgo Radiation
When adjusting for lesion size and grade, tamoxifen after surgery decreased the risk of recurrence in the same breast.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback